New pill could clear psoriasis skin in 12 weeks

NCT ID NCT07489885

Recruiting now Disease control Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This Phase 2 trial tests an experimental oral drug called D-2570 in 75 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either D-2570 or a placebo tablet for 12 weeks. The main goal is to see if the drug can achieve at least a 90% improvement in psoriasis severity (PASI-90). The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: D-2570 tablet
What this could lead to: If successful, this could point toward a new oral treatment option for moderate to severe plaque psoriasis, potentially offering better skin clearance.
What could go wrong: This is an early Phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Study Center
RECRUITING

Birmingham, Alabama, 35244, United States
Study Center
NOT_YET_RECRUITING

Phoenix, Arizona, 85008, United States
Study Center
RECRUITING

Chula Vista, California, 91910, United States
Study Center
NOT_YET_RECRUITING

Fountain Valley, California, 92708, United States
Study Center
NOT_YET_RECRUITING

Fremont, California, 94538, United States
Study Center
NOT_YET_RECRUITING

Los Angeles, California, 90017, United States
Study Center
NOT_YET_RECRUITING

Los Angeles, California, 90024, United States
Study Center
NOT_YET_RECRUITING

San Diego, California, 92123, United States
Study Center
NOT_YET_RECRUITING

Fort Lauderdale, Florida, 33308, United States
Study Center
NOT_YET_RECRUITING

Miramar, Florida, 33027, United States
Study Center
NOT_YET_RECRUITING

Ocala, Florida, 34470, United States
Study Center
NOT_YET_RECRUITING

Tampa, Florida, 33607, United States
Study Center
NOT_YET_RECRUITING

Sandy Springs, Georgia, 30328, United States
Study Center
NOT_YET_RECRUITING

Savannah, Georgia, 31419, United States
Study Center
NOT_YET_RECRUITING

Idaho Falls, Idaho, 83404, United States
Study Center
NOT_YET_RECRUITING

Clarksville, Indiana, 40241, United States
Study Center
NOT_YET_RECRUITING

Louisville, Kentucky, 40241, United States
Study Center
NOT_YET_RECRUITING

Mayfield Heights, Ohio, 44124, United States
Study Center
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19103, United States
Study Center
RECRUITING

San Antonio, Texas, 78218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.